Atria Investments’s Centessa Pharmaceuticals CNTA Stock Holding History

Atria Investments’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,332	Closed	-$490K	–	2137
2026 Q1	$490K	Sell	12,332 -260	-2%	-$6.65K	0.01%	1459
2025 Q4	$315K	Sell	12,592 -926	-7%	-$23.5K	﹤0.01%	1719
2025 Q3	$328K	Sell	13,518 -411	-3%	-$7.3K	﹤0.01%	1673
2025 Q2	$183K	Buy	13,929 +382	+3%	+$4.84K	﹤0.01%	1936
2025 Q1	$195K	Sell	13,547 -227	-2%	-$3.71K	﹤0.01%	1829
2024 Q4	$231K	Sell	13,774 -3,360	-20%	-$55.7K	﹤0.01%	1721
2024 Q3	$274K	Buy	17,134 +1,116	+7%	+$13.7K	﹤0.01%	1655
2024 Q2	$145K	Buy	+16,018	New	+$152K	﹤0.01%	1854

Atria Investments's CNTA Position: Q2 2026 in Review

Atria Investments sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 12,332 shares — an estimated $490K sold.

Atria Investments first reported a position in CNTA in Q2 2024 and held it in 8 quarters. The position peaked at $490K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Atria Investments reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Atria Investments sold 12,332 Centessa Pharmaceuticals shares in Q2 2026, an estimated $490K.
Atria Investments first reported a position in Centessa Pharmaceuticals in Q2 2024 and held it in 8 quarters.
Atria Investments's Centessa Pharmaceuticals position peaked at $490K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.